What is REGN's market cap?

$96.28B, based on the Nov 4 close of $930.67.

What is REGN's P/E ratio?

20.0× trailing-twelve-month earnings of $4.82B.

Does Regeneron Pharmaceuticals pay a dividend?

Yes. The latest regular dividend was $0.94 per share (ex-date Aug 18), an annualised yield of 0.40%.

How much of REGN is sold short?

2.1M shares, 2.2% of float, as of Oct 15, 2026.

What sector is REGN in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · REGNHealthcarePharmaceuticals

Regeneron Pharmaceuticals Inc (REGN)

$930.67−4.39%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$942.32▲ 50.05% in range

Nov 4, 2025Low $600.66 · High $973.36Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Regeneron Pharmaceuticals closed at $930.67 on Nov 4, down 4.39%, 4.4% below its 52-week closing high. Volume of 1.4M shares was 1.70× its 20-day average (above normal).

Split-adjusted performance: +26.0% over one month, +29.1% over six months, +44.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $5.12B, up 36.3% from a year earlier, with a net margin of 38.1%.

Short interest was 2.1M shares at the Oct 15 settlement (2.2% of float, 3.2 days to cover).

Market cap$96.28B103.4M shares

Revenue · quarter$5.12B+36.3% YoY

Diluted EPS$18.45+35.5% YoY

P/E · TTM20.0×P/S 5.7×

Net margin38.1%Gross 88.8%

Dividend yield0.40%$0.94 last paid

52-week range600.66 – 973.36−4.4% from high

Volume1.4M1.70× 20-day avg

Volatility · 60d38.3%Annualised

Short % of float2.2%3.2 days to cover

Net cash$6.59BCash $9.30B

Next earnings—Not scheduled

Split-adjusted performance

1W +14.4%1M +26.0%3M +20.5%6M +29.1%YTD +20.6%1Y +44.9%3Y +19.7%5Y +57.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum85

Revenue growth73

Net margin92

Value (low P/E)41

Size98

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short2.1M−0.7% vs prior

Days to cover3.2Settled Oct 15

% of float2.2%

Short vol. 10d48.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
REGNRegeneron Pharmaceuticals	$930.67	−4.39%	+29.1%	+36.3%	38.1%	20.0	$96.28B
BMYBristol-Myers Squibb	$64.19	+4.02%	+13.4%	+5.7%	25.6%	14.1	$131.21B	Compare
VRTXVertex Pharmaceuticals	$549.04	+3.44%	+28.4%	+11.8%	19.0%	35.0	$139.16B	Compare
PFEPfizer	$30.79	+2.63%	+16.1%	+2.6%	−1.6%	40.5	$175.49B	Compare
TEVATeva Pharmaceutical Industries Limited	$41.85	−0.14%	+15.2%	−0.8%	−13.9%	69.0	$48.81B	Compare
ABTAbbott Laboratories	$115.51	+5.58%	+33.8%	+13.0%	7.4%	36.8	$199.88B	Compare
ZTSZOETIS	$89.20	+7.48%	−19.8%	−0.2%	28.0%	14.1	$36.86B	Compare
RPRXRoyalty Pharma	$67.56	+1.75%	+33.2%	+16.5%	2.7%	36.9	$30.08B	Compare
ROIVRoivant Sciences	$38.23	+6.08%	+32.7%	−33.5%	−13164.8%	—	$27.61B	Compare

News about Regeneron Pharmaceuticals

All news →

Why Regeneron (REGN) Might be Well Poised for a SurgeZacks Investment Research · 14h ago▲ Positive REGN vs. ILMN: Which Stock Is the Better Value Option?Zacks Investment Research · 15h ago▲ Positive Regeneron: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 4d ago▲ Positive REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock UpZacks Investment Research · 5d ago▲ Positive Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · 5d ago▲ Positive

Quick answers

What does Regeneron Pharmaceuticals do?: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma.
What is REGN's market cap?: $96.28B, based on the Nov 4 close of $930.67.
What is REGN's P/E ratio?: 20.0× trailing-twelve-month earnings of $4.82B.
Does Regeneron Pharmaceuticals pay a dividend?: Yes. The latest regular dividend was $0.94 per share (ex-date Aug 18), an annualised yield of 0.40%.
How much of REGN is sold short?: 2.1M shares, 2.2% of float, as of Oct 15, 2026.
What sector is REGN in?: Healthcare, in the Pharmaceuticals industry.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

HQ: Tarrytown, NY15,410 employeesListed Apr 2, 1991regeneron.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology